Potensi Interaksi Obat Pada Pasien Covid-19 Terkonfirmasi Dengan Komorbid di Bangsal Ogan RSUP Dr. Mohammad Hoesin Palembang Periode April-Juni 2021

Yuniar, Yuniar; Ramadhiani, Aninditha Rachmah; Asyifa, Dini; Putri, Winda Kirana Ade; Apriliana, Winta Sari

doi:10.22146/farmaseutik.v18i1.71910

Cited by 2 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dalam memilih pengobatan Covid-19, interaksi obat Covid-19 dengan pengobatan penyakit lain harus diperhatikan. Mayoritas pasien dengan penyakit penyerta menerima polifarmasi, sehingga dapat meningkatkan potensi terjadinya interaksi obat (Yuniar et al, 2022). Berdasarkan latar belakang diatas maka peneliti tertarik untuk melakukan kajian terkait apakah ada potensi interaksi pada pengobatan pasien COVID-19 di RSUD Kota Mataram.…”

Section: Pendahuluanunclassified

Studi Potensi Interaksi Obat Pasien Covid-19 di Rumah Sakit Umum Daerah Kota Mataram

Ningrum,

Ramdaniah,

Setia Permana

et al. 2023

IJPNP

View full text Add to dashboard Cite

Covid-19 or Coronavirus disease 2019 is an acute respiratory disease caused by the Severe Acute Respiratory Syndrom Coronavirus (SARS CoV-2), which entered Indonesia in early 2020. Data on Covid-19 in West Nusa Tenggara Province (NTB) in November reported 4,550 cases. Covid-19 can cause disorders in the respiratory system, acute pneumonia to death, so researchers conducted this study which aims to see how potential drug interactions exist in patients who get Covid-19 therapy while being treated at the Mataram City Hospital for the January-December 2021 period. This research is a descriptive study conducted to get an idea of whether there are potential drug interactions that occur by conducting research objectively. Data obtained from primary data, namely medical records of patients diagnosed with Covid-19 and treated in isolation rooms. Obtained as many as 95 medical record data of Covid-19 patients in the period January - December 2021. This research is a descriptive study conducted to get an idea of whether there are potential drug interactions that occur by conducting research objectively. Data obtained from primary data, namely medical records of patients diagnosed with Covid-19 and treated in isolation rooms. As many as 95 medical record data for Covid-19 patients were obtained in the period January – December 2021. Of the 95 patients obtained, it was found that the category of drug interactions with drugs based on severity was 5.26%, moderate interactions were 42.10%, and major interactions were 3.15%. The conclusion of this study is that the most common potential drug interactions were found with moderate severity with a percentage of 42.10% of 95 patients. ABSTRAK Covid-19 atau Coronavirus disease 2019 merupakan suatu penyakit pernapasan akut yang disebabkan oleh Severe Acute Respiratory Syndrom Coronavirus (SARS CoV-2), yang masuk ke Indonesia di awal tahun 2020. Data Covid-19 di Provinsi Nusa Tenggara Barat (NTB) pada bulan November dilaporkan sebanyak 4.550 kasus. Covid-19 dapat menyebakan gangguan pada sistem pernapasan, pneumonia akut hingga kematian, sehingga peneliti melakukan penelitian ini yang bertujuan untuk melihat bagaimana potensi adanya interaksi obat pada pasien yang mendapatkan terapi Covid-19 selama di rawat di RSUD Kota Mataram periode Januari-Desember 2021. Penelitian ini merupakan penelitian deskriptif yang dilakukan untuk mendapatkan gambaran apakah ada potensi interaksi obat yang terjadi dengan melakukan penelitian secara objektif. Data diperoleh dari data primer yaitu rekam medis pasien yang terdiagnosa Covid-19 dan dirawat di ruang isolasi. Diperoleh sebanyak 95 data rekam medis pasien Covid-19 pada periode Januari – Desember 2021. Dari 95 pasien yang diperoleh, ditemukan diperoleh kategori interaksi obat dengan obat berdasarkan keparahan yaitu interaksi minor sebanyak 5,26% , interaksi moderate 42,10% , dan interaksi mayor sebanyak 3,15%. Kesimpulan penelitian ini adalah potensi interaksi obat yang paling banyak ditemukan yaitu dengan tingkat keparahan moderate dengan persentase sebesar yaitu 42,10% dari 95 pasien.

show abstract

Section: Pendahuluanunclassified

Studi Potensi Interaksi Obat Pasien Covid-19 di Rumah Sakit Umum Daerah Kota Mataram

Ningrum,

Ramdaniah,

Setia Permana

et al. 2023

IJPNP

View full text Add to dashboard Cite

show abstract

“…Research on drug interactions among hospitalized COVID-19 patients in Indonesia is still limited, including those conducted by Larasati, Nisa & Yumna (2021) at a hospital in West Java and by Yuniar Ramadhiani et al. (2021) at a hospital in Palembang, South Sumatra.…”

Section: Introductionmentioning

confidence: 99%

“…Both studies were conducted during different periods of COVID-19, one was in August–December 2020 ( Larasati, Nisa & Yumna, 2021 ) and the other was in April–June 2021 ( Yuniar Ramadhiani et al, 2021 ). The pattern of drugs used for COVID-19 were different between the earlier and the later period of the disease following new guidelines and related-studies ( Cantudo-Cuenca et al, 2021 ; Cattaneo et al, 2020 ; Larasati, Nisa & Yumna, 2021 ; Martinez-López-de Castro et al, 2020 ; Mahboobipour & Baniasadi, 2020 ; Yuniar Ramadhiani et al, 2021 ). Our study aims to identify the pattern of pDDIs in hospitalized COVID-19 patients with comorbidities and the associated factors, especially in the second wave of the disease in Indonesia.…”

Section: Introductionmentioning

confidence: 99%

Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities

Rahmadani,

Irawati,

Wibowo

et al. 2023

PeerJ

View full text Add to dashboard Cite

Background Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later period of the disease are still limited. This study aims to identify the pattern of pDDIs in hospitalized COVID-19 patients with comorbidities and their associated factors, especially in the second wave of the disease in Indonesia. Methods This study was a longitudinal-retrospective study observing hospitalized COVID-19 patients with comorbidities using medical record data in June–August 2021 at a public hospital in a region in Indonesia. pDDIs were identified using the Lexicomp® database. Data were descriptively analyzed. Factors associated with important pDDIs were analyzed in multivariate logistic regression model. Results A total of 258 patients with a mean age of 56.99 ± 11.94 years met the inclusion criteria. Diabetes mellitus was the most common comorbidity experienced by 58.14% of the patients. More than 70% of the patients had one comorbidity and the average number of administered drugs was 9.55 ± 2.71 items per patient. Type D pDDIs, which required modification of therapeutic regimens, amounted to 21.55% of the total interactions. Only the number of drugs was significantly and independently associated with type D pDDIs (adjusted odds ratio 1.47 [1.23–1.75], p < 0.01). Conclusion The drugs involved in the pDDIs of hospitalized COVID-19 patients with comorbidities may differ depending on the disease periods, hospital settings, or countries. This study was small, single center, and of short duration. However, it may give a glimpse of important pDDIs during the delta variant of COVID-19 in a similar limited-resource setting. Further studies are needed to confirm the clinical significance of these pDDIs.

show abstract

Potensi Interaksi Obat Pada Pasien Covid-19 Terkonfirmasi Dengan Komorbid di Bangsal Ogan RSUP Dr. Mohammad Hoesin Palembang Periode April-Juni 2021

Cited by 2 publications

References 6 publications

Studi Potensi Interaksi Obat Pasien Covid-19 di Rumah Sakit Umum Daerah Kota Mataram

Studi Potensi Interaksi Obat Pasien Covid-19 di Rumah Sakit Umum Daerah Kota Mataram

Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities

Contact Info

Product

Resources

About